docosanol · Haleon Us Holdings · NDA 020941
Abreva
Earliest generic entry, as listed
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 25 Oct 2026Generic approved · 020941-00123 Oct 2025
- 25 Oct 2026Generic approved · 020941-00131 Jul 2026
- 25 Oct 2026Generic approved · 020941-0013 Oct 2025
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 020941 · 001 · RLD | cream, topical | 10% | open |